Special Offer: Get 50% off your first 2 months when you do one of the following
Personalized offer codes will be given in each session
Name
Jeremy Skillington
Title
CEO
Bio
Jeremy began his biotechnology career in the Business Development group of Genentech, Inc in California in 2002. At Genentech he was responsible for executing over 40 licensing, investment and collaboration transactions. Returning to Ireland in 2009, he then led Business Development and was a member of the Senior Management team at Opsona Therapeutics Ltd before becoming a founder and CEO of immuno-oncology company TriMod Therapeutics Ltd.
He joined German investment fund HS Lifesciences GmbH in 2014 to provide start-up and business development support to portfolio companies ImmunoQure AG and Ethris GmbH.
He joined Inflazome on its founding in 2016 and was instrumental in their acquisition by Roche in September, 2020 for €380M (£325M) upfront and significant downstream milestone payments.
Jeremy studied Biochemistry at the National University of Ireland, Galway where he was awarded his Ph.D. He performed his post-doctoral research at the University of California, San Francisco in the lab of Prof Rik Derynck.
He joined German investment fund HS Lifesciences GmbH in 2014 to provide start-up and business development support to portfolio companies ImmunoQure AG and Ethris GmbH.
He joined Inflazome on its founding in 2016 and was instrumental in their acquisition by Roche in September, 2020 for €380M (£325M) upfront and significant downstream milestone payments.
Jeremy studied Biochemistry at the National University of Ireland, Galway where he was awarded his Ph.D. He performed his post-doctoral research at the University of California, San Francisco in the lab of Prof Rik Derynck.
